These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36824056)

  • 41. Eradication of minimal residual disease in chronic lymphocytic leukemia.
    Schweighofer CD; Hallek M; Wendtner CM
    Curr Hematol Malig Rep; 2008 Jan; 3(1):54-60. PubMed ID: 20425447
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparison of the sensitivity of flow cytometry and bone marrow biopsy in the detection of minimal residual disease in chronic lymphocytic leukemia.
    Maloum K; Charlotte F; Divine M; Cazin B; Lesty C; Merle-Béral H;
    Haematologica; 2006 Jun; 91(6):860-1. PubMed ID: 16769593
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.
    Fürstenau M; Weiss J; Giza A; Franzen F; Robrecht S; Fink AM; Fischer K; Schneider C; Tausch E; Stilgenbauer S; Ritgen M; Schilhabel A; Brüggemann M; Eichhorst B; Hallek M; Cramer P
    Clin Cancer Res; 2022 Oct; 28(19):4203-4211. PubMed ID: 35594173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
    Montillo M; Schinkoethe T; Elter T
    Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Automated Flow Cytometric MRD Assessment in Childhood Acute B- Lymphoblastic Leukemia Using Supervised Machine Learning.
    Reiter M; Diem M; Schumich A; Maurer-Granofszky M; Karawajew L; Rossi JG; Ratei R; Groeneveld-Krentz S; Sajaroff EO; Suhendra S; Kampel M; Dworzak MN;
    Cytometry A; 2019 Sep; 95(9):966-975. PubMed ID: 31282025
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia.
    Algrin C; Golmard JL; Michallet M; Reman O; Huynh A; Perrot A; Sirvent A; Plesa A; Salaun V; Béné MC; Bories D; Tournilhac O; Merle-Béral H; Leblond V; Le Garff-Tavernier M; Dhedin N
    Eur J Haematol; 2017 Apr; 98(4):363-370. PubMed ID: 27943415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
    Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
    Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
    García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
    Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.
    Logan AC; Gao H; Wang C; Sahaf B; Jones CD; Marshall EL; Buño I; Armstrong R; Fire AZ; Weinberg KI; Mindrinos M; Zehnder JL; Boyd SD; Xiao W; Davis RW; Miklos DB
    Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21194-9. PubMed ID: 22160699
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease.
    Momen N; Tario J; Fu K; Qian YW
    J Hematop; 2023 Jun; 16(2):85-94. PubMed ID: 38175444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: The Cinderella method.
    Hoffmann J; Thrun MC; Röhnert MA; von Bonin M; Oelschlägel U; Neubauer A; Ultsch A; Brendel C
    Cytometry A; 2023 Apr; 103(4):304-312. PubMed ID: 36030398
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessing minimal residual disease in chronic lymphocytic leukemia.
    Rawstron AC; Hillmen P
    Curr Hematol Malig Rep; 2008 Jan; 3(1):47-53. PubMed ID: 20425446
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Machine learning optimized multiparameter radar plots for B-cell acute lymphoblastic leukemia minimal residual disease analysis.
    Shopsowitz KE; Liu L; Setiadi A; Al-Bakri M; Vercauteren S
    Cytometry B Clin Cytom; 2022 Sep; 102(5):342-352. PubMed ID: 35726954
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders.
    Pedreira CE; Costa ES; Almeida J; Fernandez C; Quijano S; Flores J; Barrena S; Lecrevisse Q; Van Dongen JJ; Orfao A;
    Cytometry A; 2008 Dec; 73A(12):1141-50. PubMed ID: 18836994
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
    Thompson PA; Wierda WG
    Blood; 2016 Jan; 127(3):279-86. PubMed ID: 26576865
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Measurable residual disease in adult acute myeloid leukaemia: evaluation of a multidimensional 'radar' flow cytometric plot analysis method.
    van der Linde R; Smith S; Brown DA; Sasson SC; Tegg E
    Pathology; 2023 Apr; 55(3):383-390. PubMed ID: 36725446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
    Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
    Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
    Cheson BD; Mato AR
    Clin Adv Hematol Oncol; 2020 Jun; 18 Suppl 10(6):1-20. PubMed ID: 33843867
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.
    Noy A; Verma R; Glenn M; Maslak P; Rahman ZU; Keenan JR; Weiss M; Filippa D; Zelenetz AD
    Blood; 2001 Apr; 97(7):1929-36. PubMed ID: 11264154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.